Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited have entered into a licensing and supply agreement to co-market Semaglutide Injection in India. The agreement allows Zydus to manufacture and supply the product, while Torrent Pharma will co-market it under the brand name SEMBOLICTM, leveraging its strong presence in chronic therapies across the country.
Zydus will market the innovative formulation under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM. The formulation of Semaglutide Injection (15 mg/3 ml) comes in a prefilled cartridge administered using a reusable pen device, designed to enhance patient convenience and improve treatment adherence.
Semaglutide is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy or in combination with other diabetes treatments. It is also used for chronic weight management in adults with obesity or overweight conditions with weight-related comorbidities.
The partnership combines Zydus’s product development and manufacturing capabilities with Torrent Pharma’s market expertise, aiming to enhance patient access to advanced GLP-1 therapies for metabolic disorders.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).